BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1

@inproceedings{Zhang2016BETBI,
  title={BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1},
  author={Zhenfeng Zhang and Pengfei Ma and Ying Ying Jing and Ying Yan and Mei-Chun Cai and Meiying Zhang and Shengzhe Zhang and Huixin Peng and Zhi-Liang Ji and Wen Di and Zhenyu Gu and Wei-Qiang Gao and Guanglei Zhuang},
  booktitle={Theranostics},
  year={2016}
}
Ovarian cancer is responsible for the highest mortality among all gynecologic malignancies, and novel therapies are urgently needed to improve patient outcome. Here we performed an integrative genomic analysis and identified the bromodomain and extraterminal domain (BET) protein BRD4 as a potential therapeutic target in ovarian cancer. Suppression of BRD4 using small-molecule BET inhibitors JQ1 and I-BET151, or dual kinase-bromodomain inhibitor volasertib, led to robust and broad antitumor… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
13 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…